公开(公告)号：US11248264B2

公开(公告)日：2022-02-15

申请号：US16920286

申请日：2020-07-02

Applicant: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH ,  BioNTech SE

Inventor： Ugur Sahin ,  Sebastian Kreiter ,  Mustafa Diken ,  Jan Diekmann ,  Michael Koslowski ,  Cedrik Britten ,  John Christopher Castle ,  Martin Löwer ,  Bernhard Renard ,  Tana Omokoko ,  Johannes Hendrikus De Graaf

IPC: A61K39/00 ,  C12Q1/6869 ,  G16B20/00 ,  G16B40/00 ,  C12Q1/6886 ,  G16B20/20

Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.

公开(公告)号：US20230190898A1

公开(公告)日：2023-06-22

申请号：US17964839

申请日：2022-10-12

Applicant: BioNTech SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG

Inventor： Ugur Sahin ,  Claudia Paret ,  Kirsten Vormbrock ,  Christian Bender ,  Jan Diekmann

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K2039/53 ,  A61K2039/572 ,  A61K2039/605 ,  A61K2039/627 ,  A61K2039/55561

Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.

公开(公告)号：US20220282322A1

公开(公告)日：2022-09-08

申请号：US17576170

申请日：2022-01-14

Applicant: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG ,  BioNTech SE

Inventor： Ugur Sahin ,  Sebastian Kreiter ,  Mustafa Diken ,  Jan Diekmann ,  Michael Koslowski ,  Cedrik Britten ,  John Christopher Castle ,  Martin Löwer ,  Bernhard Renard ,  Tana Omokoko ,  Johannes Hendrikus De Graaf

IPC: C12Q1/6869 ,  A61K39/00 ,  G16B20/00 ,  G16B40/00 ,  C12Q1/6886 ,  G16B20/20

Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.

公开(公告)号：US20240043527A1

公开(公告)日：2024-02-08

申请号：US17915567

申请日：2021-03-29

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Claudia Lindemann ,  Jan Diekmann ,  Kerstin Brettschneider ,  Hayat Bähr-Mahmud ,  Ursula Ellinghaus ,  Leyla Fischer ,  Christiane Stadler ,  Özlem Türeci

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/28 ,  A61P35/00 ,  C07K2317/522 ,  C07K2317/14

Abstract: The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example, in some embodiments, such RNA technologies can be useful for treatment of Claudin-18.2 positive cancer, including, e.g, but not limited to biliary cancers, ovarian cancers, gastric cancers, gastro-esophageal cancers, pancreatic cancers. In some embodiments, such RNA technologies can be used in combination therapy (e.g, in combination with a chemotherapeutic agent).

公开(公告)号：US11504419B2

公开(公告)日：2022-11-22

申请号：US16172063

申请日：2018-10-26

Applicant: BioNTech SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH

Inventor： Ugur Sahin ,  Claudia Paret ,  Kirsten Vormbrock ,  Christian Bender ,  Jan Diekmann

IPC: A61P35/00 ,  A61K39/00

Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.